Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.70 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582671 | 0.88 | MCHR1 (0.83) | MCHR1DGAT1MEN1NPC1RAB9A | |
| SCHEMBL7255504 | 0.87 | MCHR1 (0.79) | MCHR1DGAT1MEN1NPC1RAB9A | |
| SCHEMBL7254564 | 0.85 | MCHR1 (0.81) | MCHR1DGAT1MEN1NPC1RAB9A | |
| SCHEMBL14454778 | 0.85 | MCHR1 (0.88) | MCHR1NPC1RAB9A | |
| SCHEMBL14454874 | 0.83 | MCHR1 (0.75) | MCHR1MEN1KMT2A | |
| SCHEMBL7254682 | 0.83 | MCHR1 (0.76) | MCHR1DGAT1MEN1NPC1RAB9A | |
| SCHEMBL5774124 | 0.83 | MCHR1 (0.68) | MCHR1ALDH1A1NPC1RAB9A | |
| SCHEMBL7260545 | 0.83 | MCHR1 (0.73) | MCHR1DGAT1MEN1NPC1RAB9A | |
| SCHEMBL7254656 | 0.83 | MCHR1 (0.76) | MCHR1DGAT1MEN1NPC1RAB9A | |
| SCHEMBL5582793 | 0.83 | MCHR1 (0.88) | MCHR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885DGAT1 4231/4885KDM4E 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.